Budesonide and Luminol Synergistic Combination for COPD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Long-term administration of budesonide, a commonly used glucocorticoid, is associated with several serious side effects, and there is a medical need to reduce the dosage while maintaining its therapeutic effectiveness and minimizing adverse effects.
Innovation Solution
The combination of budesonide with 5-amino-2,3-dihydro-1,4-phthalazinedione or its sodium salt, which acts synergistically to enhance the anti-inflammatory effects of budesonide, allowing for a reduction in budesonide dosage without compromising its efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If budesonide is administered long-term, then therapeutic effectiveness is maintained, but serious side effects occur
Solution Approach 1:
The patent combines budesonide with 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) to create a synergistic pharmaceutical combination. This merging of two substances allows the therapeutic effectiveness to be maintained while reducing the dosage of budesonide, thereby minimizing its harmful side effects. The combination exhibits supraadditive effects, where the combined action is greater than the sum of individual effects.
Solution Approach 2:
The patent changes the dosing parameter by reducing the amount of budesonide administered when used in combination with luminol. This parameter change is enabled by the synergistic interaction between the two drugs, which allows achieving the same therapeutic effect at lower budesonide doses, thus reducing harmful effects while maintaining reliability.
2Object-affected harmful factors
If budesonide dosage is reduced, then side effects are minimized, but therapeutic effectiveness may be compromised
Solution Approach 1:
Luminol acts as an intermediary substance that enhances the anti-inflammatory effects of budesonide. When administered together, luminol mediates the therapeutic action, allowing reduced budesonide dosing while maintaining effectiveness. The synergistic interaction ensures that the combined preparation achieves the desired therapeutic outcome at lower individual drug doses.
Solution Approach 2:
The patent creates a composite pharmaceutical preparation combining budesonide and luminol. This composite material exhibits synergistic properties where the combination produces greater anti-inflammatory effect than either drug alone, enabling dose reduction of budesonide while preserving therapeutic effectiveness and reducing side effects.
3Reliability
If higher doses of budesonide are used, then therapeutic effectiveness is achieved, but adverse drug reactions increase
Solution Approach 1:
The patent merges budesonide with luminol to create a synergistic combination that achieves therapeutic effectiveness at lower budesonide doses. This combining approach reduces the overall drug load and minimizes adverse reactions while maintaining the desired anti-inflammatory effect through the synergistic interaction between the two agents.
Solution Approach 2:
The patent changes the dosing parameter by using lower budesonide doses in the context of luminol combination therapy. This parameter change is supported by the synergistic mechanism, which ensures that therapeutic effectiveness is maintained even at reduced doses, thereby decreasing the frequency and severity of adverse drug reactions.
Data Source
AI summary
The present invention relates to a combination of budesonide and 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts. This pharmaceutical combination shall be used in the treatment of chronic inflammatory diseases, especially COPD, asthma, Crohn's disease, colitis ulcerosa and autoimmune hepatitis. The invention relates in particular to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt in this combination. Pharmaceutical compositions, advantageous formulation techniques and a method of treatment are disclosed.